"sample_name"	"alt_sample_name"	"unique_patient_ID"	"sample_type"	"surgery_type"	"histological_type"	"summarygrade"	"summarystage"	"T"	"substage"	"G"	"N"	"M"	"visceral_metastasis"	"lymphovascular_invasion"	"age"	"gender"	"ecog_ps"	"neoadjuvant_chemo"	"neoadjuvant_regimen"	"adjuvant_chemo"	"adjuvant_regimen"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"dfs_event"	"smoking_status"	"smoking_package_years"	"nomogram_score"	"batch"	"uncurated_author_metadata"
"GSM786491"	"1_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	64	"m"	NA	"n"	NA	"n"	NA	3159	"norecurrence"	3159	"deceased"	"doc"	"former"	20	81.44001734	"2005-06-14"	"title: 1_pT2///geo_accession: GSM786491///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 64.06///characteristics_ch1.3: survival.months: 103.7864///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 81.44001734///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 20///characteristics_ch1.18: recurrence free survival months (distant and local): 103.7864///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786491/GSM786491.CEL.gz///data_row_count: 54675"
"GSM786492"	"2_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	1	NA	NA	62	"m"	NA	"n"	NA	"y"	NA	217	"recurrence"	401	"deceased"	"dod"	"never"	NA	81.71198473	"2005-06-10"	"title: 2_pT2///geo_accession: GSM786492///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 62.14///characteristics_ch1.3: survival.months: 13.17454///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 81.71198473///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 7.129363///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786492/GSM786492.CEL.gz///data_row_count: 54675"
"GSM786493"	"3_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	66	"f"	NA	"n"	NA	"n"	NA	316	"recurrence"	602	"deceased"	"dod"	"current"	80	79.95740897	"2005-06-10"	"title: 3_pT2///geo_accession: GSM786493///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 65.96///characteristics_ch1.3: survival.months: 19.77823///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 79.95740897///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 80///characteristics_ch1.18: recurrence free survival months (distant and local): 10.38193///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786493/GSM786493.CEL.gz///data_row_count: 54675"
"GSM786494"	"4_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	56	"m"	NA	"n"	NA	"n"	NA	473	"recurrence"	500	"deceased"	"dod"	"former"	35	11.08510015	"2005-06-10"	"title: 4_pT4///geo_accession: GSM786494///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 56.1///characteristics_ch1.3: survival.months: 16.4271///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 11.08510015///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 35///characteristics_ch1.18: recurrence free survival months (distant and local): 15.54004///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786494/GSM786494.CEL.gz///data_row_count: 54675"
"GSM786495"	"5_pT4"	NA	"tumor"	"rc"	"cis"	"high"	"invasive"	4	NA	NA	0	0	NA	NA	68	"f"	NA	"n"	NA	"n"	NA	400	"norecurrence"	400	"deceased"	"doc"	"former"	20	49.06355452	"2005-06-10"	"title: 5_pT4///geo_accession: GSM786495///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 68///characteristics_ch1.3: survival.months: 13.14168///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC/CIS///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 49.06355452///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 20///characteristics_ch1.18: recurrence free survival months (distant and local): 13.14168///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786495/GSM786495.CEL.gz///data_row_count: 54675"
"GSM786496"	"6_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	1	NA	NA	70	"m"	NA	"n"	NA	"n"	NA	83	"recurrence"	135	"deceased"	"dod"	"former"	50	41.39963921	"2005-06-10"	"title: 6_pT3///geo_accession: GSM786496///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 69.93///characteristics_ch1.3: survival.months: 4.435318///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 41.39963921///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 50///characteristics_ch1.18: recurrence free survival months (distant and local): 2.726899///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786496/GSM786496.CEL.gz///data_row_count: 54675"
"GSM786497"	"7_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	1	0	NA	NA	65	"m"	NA	"n"	NA	"n"	NA	2674	"norecurrence"	2674	"deceased"	"doc"	"current"	50	50.12822813	"2005-06-10"	"title: 7_pT1///geo_accession: GSM786497///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 65///characteristics_ch1.3: survival.months: 87.85216///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 50.12822813///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 50///characteristics_ch1.18: recurrence free survival months (distant and local): 87.85216///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786497/GSM786497.CEL.gz///data_row_count: 54675"
"GSM786498"	"8_pT3"	NA	"tumor"	"rc"	"cis"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	69	"m"	NA	"n"	NA	"n"	NA	5278	"norecurrence"	5278	"living"	"ned"	"never"	NA	64.48725601	"2005-06-10"	"title: 8_pT3///geo_accession: GSM786498///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 69.44///characteristics_ch1.3: survival.months: 173.4045///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC/CIS///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 64.48725601///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 173.4045///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 2///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786498/GSM786498.CEL.gz///data_row_count: 54675"
"GSM786499"	"9_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	1	NA	NA	47	"m"	NA	"n"	NA	"y"	NA	2927	"recurrence"	3301	"deceased"	"dod"	"former"	30	76.49581054	"2005-06-10"	"title: 9_pT2///geo_accession: GSM786499///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 47.47///characteristics_ch1.3: survival.months: 108.4517///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 76.49581054///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 30///characteristics_ch1.19: recurrence free survival months (distant and local): 96.16427///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786499/GSM786499.CEL.gz///data_row_count: 54675"
"GSM786500"	"10_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	0	NA	NA	78	"f"	NA	"n"	NA	"n"	NA	5342	"norecurrence"	5342	"deceased"	"doc"	"former"	20	52.61069907	"2005-06-10"	"title: 10_pT3///geo_accession: GSM786500///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 77.9///characteristics_ch1.3: survival.months: 175.5072///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 52.61069907///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 20///characteristics_ch1.18: recurrence free survival months (distant and local): 175.5072///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786500/GSM786500.CEL.gz///data_row_count: 54675"
"GSM786501"	"11_pT1"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	1	NA	NA	0	0	NA	NA	67	"m"	NA	"n"	NA	"n"	NA	5103	"norecurrence"	5103	"living"	"ned"	"never"	NA	90.1987881	"2005-06-10"	"title: 11_pT1///geo_accession: GSM786501///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 66.56///characteristics_ch1.3: survival.months: 167.655///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 90.1987881///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 167.655///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786501/GSM786501.CEL.gz///data_row_count: 54675"
"GSM786502"	"12_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	1	NA	NA	65	"m"	NA	"n"	NA	"n"	NA	3043	"recurrence"	3126	"deceased"	"dod"	"never"	NA	40.62923558	"2005-06-10"	"title: 12_pT2///geo_accession: GSM786502///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 65.11///characteristics_ch1.3: survival.months: 102.7023///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 40.62923558///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 99.97536///characteristics_ch1.18: recurrence/dod: Yes///characteristics_ch1.19: cluster: 2///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786502/GSM786502.CEL.gz///data_row_count: 54675"
"GSM786503"	"13_pT3"	NA	"tumor"	"rc"	"squamous"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	77	"m"	NA	"n"	NA	"n"	NA	12	"norecurrence"	12	"deceased"	"doc"	"former"	45	61.80483246	"2005-06-10"	"title: 13_pT3///geo_accession: GSM786503///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 76.93///characteristics_ch1.3: survival.months: 0.3942505///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC/Squamous///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 61.80483246///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 45///characteristics_ch1.18: recurrence free survival months (distant and local): 0.3942505///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786503/GSM786503.CEL.gz///data_row_count: 54675"
"GSM786504"	"14_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	68	"m"	NA	"n"	NA	"y"	NA	223	"recurrence"	330	"deceased"	"dod"	"former"	80	1	"2005-05-12"	"title: 14_pT4///geo_accession: GSM786504///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 68.04///characteristics_ch1.3: survival.months: 10.84189///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 1///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 80///characteristics_ch1.19: recurrence free survival months (distant and local): 7.326489///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786504/GSM786504.CEL.gz///data_row_count: 54675"
"GSM786505"	"15_pT4"	NA	"tumor"	"rc"	"squamous"	"high"	"invasive"	4	NA	NA	0	0	NA	NA	68	"f"	NA	"n"	NA	"n"	NA	95	"norecurrence"	95	"deceased"	"doc"	"current"	40	47.79618735	"2005-06-14"	"title: 15_pT4///geo_accession: GSM786505///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 68.03///characteristics_ch1.3: survival.months: 3.12115///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC/Squamous///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 47.79618735///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 40///characteristics_ch1.18: recurrence free survival months (distant and local): 3.12115///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786505/GSM786505.CEL.gz///data_row_count: 54675"
"GSM786506"	"16_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	73	"m"	NA	"n"	NA	"n"	NA	53	"recurrence"	102	"deceased"	"dod"	"current"	120	21.52250158	"2005-06-14"	"title: 16_pT3///geo_accession: GSM786506///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 72.77///characteristics_ch1.3: survival.months: 3.351129///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 21.52250158///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 120///characteristics_ch1.18: recurrence free survival months (distant and local): 1.741273///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786506/GSM786506.CEL.gz///data_row_count: 54675"
"GSM786507"	"17_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	0	NA	NA	60	"f"	NA	"n"	NA	"n"	NA	20	"norecurrence"	20	"living"	"ned"	"former"	20	28.61319836	"2005-06-14"	"title: 17_pT3///geo_accession: GSM786507///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 59.65///characteristics_ch1.3: survival.months: 0.6570842///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 28.61319836///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 20///characteristics_ch1.18: recurrence free survival months (distant and local): 0.6570842///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786507/GSM786507.CEL.gz///data_row_count: 54675"
"GSM786508"	"18_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	51	"m"	NA	"n"	NA	"y"	NA	253	"recurrence"	357	"deceased"	"dod"	"former"	10	69.75442714	"2005-08-03"	"title: 18_pT3///geo_accession: GSM786508///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 51.33///characteristics_ch1.3: survival.months: 11.72895///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 69.75442714///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 10///characteristics_ch1.19: recurrence free survival months (distant and local): 8.312115///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786508/GSM786508.CEL.gz///data_row_count: 54675"
"GSM786509"	"19_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	NA	0	NA	NA	73	"m"	NA	"n"	NA	"n"	NA	953	"norecurrence"	953	"living"	"ned"	"current"	10	25.40171907	"2005-08-03"	"title: 19_pT2///geo_accession: GSM786509///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 73.32///characteristics_ch1.3: survival.months: 31.31006///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 25.40171907///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 10///characteristics_ch1.18: recurrence free survival months (distant and local): 31.31006///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786509/GSM786509.CEL.gz///data_row_count: 54675"
"GSM786510"	"20_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	57	"m"	NA	"y"	NA	"y"	NA	102	"recurrence"	250	"deceased"	"dod"	"former"	35	8.270066426	"2005-08-03"	"title: 20_pT4///geo_accession: GSM786510///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 56.61///characteristics_ch1.3: survival.months: 8.213552///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 8.270066426///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: Yes///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 35///characteristics_ch1.19: recurrence free survival months (distant and local): 3.351129///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786510/GSM786510.CEL.gz///data_row_count: 54675"
"GSM786511"	"21_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	0	NA	NA	78	"m"	NA	"n"	NA	"n"	NA	751	"norecurrence"	751	"deceased"	"doc"	"former"	120	4.925223883	"2005-05-12"	"title: 21_pT4///geo_accession: GSM786511///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 78.08///characteristics_ch1.3: survival.months: 24.67351///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 4.925223883///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 120///characteristics_ch1.18: recurrence free survival months (distant and local): 24.67351///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786511/GSM786511.CEL.gz///data_row_count: 54675"
"GSM786512"	"22_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	69	"m"	NA	"n"	NA	"y"	NA	247	"recurrence"	405	"deceased"	"dod"	"former"	5	1	"2005-08-03"	"title: 22_pT3///geo_accession: GSM786512///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 68.75///characteristics_ch1.3: survival.months: 13.30595///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 1///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 5///characteristics_ch1.19: recurrence free survival months (distant and local): 8.11499///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786512/GSM786512.CEL.gz///data_row_count: 54675"
"GSM786513"	"23_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	NA	0	NA	NA	69	"m"	NA	"n"	NA	"n"	NA	33	"norecurrence"	33	"deceased"	"doc"	"former"	NA	36.09372092	"2005-06-14"	"title: 23_pT4///geo_accession: GSM786513///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 69.49///characteristics_ch1.3: survival.months: 1.084189///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 36.09372092///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: unk///characteristics_ch1.18: recurrence free survival months (distant and local): 1.084189///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786513/GSM786513.CEL.gz///data_row_count: 54675"
"GSM786514"	"24_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	62	"m"	NA	"n"	NA	"y"	NA	136	"recurrence"	223	"deceased"	"dod"	"former"	10	9.672482387	"2005-05-12"	"title: 24_pT4///geo_accession: GSM786514///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 62.08///characteristics_ch1.3: survival.months: 7.326489///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 9.672482387///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 10///characteristics_ch1.19: recurrence free survival months (distant and local): 4.468172///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786514/GSM786514.CEL.gz///data_row_count: 54675"
"GSM786515"	"25_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	73	"f"	NA	"n"	NA	"n"	NA	100	"norecurrence"	100	"deceased"	"doc"	"never"	NA	60.78974289	"2005-05-12"	"title: 25_pT3///geo_accession: GSM786515///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 72.72///characteristics_ch1.3: survival.months: 3.285421///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 60.78974289///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 3.285421///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786515/GSM786515.CEL.gz///data_row_count: 54675"
"GSM786516"	"26_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	NA	1	NA	NA	72	"f"	NA	"n"	NA	"y"	NA	251	"recurrence"	439	"deceased"	"dod"	"former"	60	34.37579285	"2005-05-13"	"title: 26_pT4///geo_accession: GSM786516///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 72.4///characteristics_ch1.3: survival.months: 14.423///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 34.37579285///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 60///characteristics_ch1.19: recurrence free survival months (distant and local): 8.246407///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786516/GSM786516.CEL.gz///data_row_count: 54675"
"GSM786517"	"27_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	0	0	NA	NA	59	"m"	NA	"n"	NA	"n"	NA	1733	"norecurrence"	1733	"living"	"ned"	"never"	NA	81.96959756	"2005-05-12"	"title: 27_pT1///geo_accession: GSM786517///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 59.39///characteristics_ch1.3: survival.months: 56.93634///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 81.96959756///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 56.93634///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786517/GSM786517.CEL.gz///data_row_count: 54675"
"GSM786518"	"28_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	75	"m"	NA	"n"	NA	"y"	NA	254	"recurrence"	1775	"deceased"	"dod"	"current"	60	21.96386456	"2005-06-14"	"title: 28_pT3///geo_accession: GSM786518///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 74.61///characteristics_ch1.3: survival.months: 58.31622///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 21.96386456///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 60///characteristics_ch1.19: recurrence free survival months (distant and local): 8.344969///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786518/GSM786518.CEL.gz///data_row_count: 54675"
"GSM786519"	"29_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	58	"m"	NA	"n"	NA	"n"	NA	88	"recurrence"	151	"deceased"	"dod"	"former"	70	17.30881569	"2005-06-14"	"title: 29_pT3///geo_accession: GSM786519///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 58.15///characteristics_ch1.3: survival.months: 4.960986///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 17.30881569///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 70///characteristics_ch1.18: recurrence free survival months (distant and local): 2.89117///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786519/GSM786519.CEL.gz///data_row_count: 54675"
"GSM786520"	"30_pT4"	NA	"tumor"	"rc"	"squamous"	"high"	"invasive"	4	NA	NA	0	1	NA	NA	53	"f"	NA	"n"	NA	"y"	NA	61	"recurrence"	283	"deceased"	"dod"	"former"	NA	46.67259699	"2005-06-14"	"title: 30_pT4///geo_accession: GSM786520///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 52.99///characteristics_ch1.3: survival.months: 9.297741///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC/Squamous///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 46.67259699///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: unk///characteristics_ch1.19: recurrence free survival months (distant and local): 2.004107///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786520/GSM786520.CEL.gz///data_row_count: 54675"
"GSM786521"	"31_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	65	"m"	NA	"n"	NA	"y"	NA	336	"recurrence"	385	"deceased"	"dod"	"former"	5	9.39539484	"2005-05-12"	"title: 31_pT4///geo_accession: GSM786521///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 64.53///characteristics_ch1.3: survival.months: 12.64887///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 9.39539484///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 5///characteristics_ch1.19: recurrence free survival months (distant and local): 11.03901///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: NA///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786521/GSM786521.CEL.gz///data_row_count: 54675"
"GSM786522"	"32_pT3"	NA	"tumor"	"rc"	"squamous"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	56	"m"	NA	"n"	NA	"y"	NA	2208	"norecurrence"	2208	"living"	"ned"	"current"	60	67.59430251	"2005-05-13"	"title: 32_pT3///geo_accession: GSM786522///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 56.47///characteristics_ch1.3: survival.months: 72.54209///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC/Squamous///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 67.59430251///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 60///characteristics_ch1.19: recurrence free survival months (distant and local): 72.54209///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786522/GSM786522.CEL.gz///data_row_count: 54675"
"GSM786523"	"33_pTa"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	0	NA	NA	0	0	NA	NA	73	"m"	NA	"n"	NA	"n"	NA	2743	"recurrence"	2743	"deceased"	"dod"	"former"	10	89.88210291	"2005-05-13"	"title: 33_pTa///geo_accession: GSM786523///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 73.42///characteristics_ch1.3: survival.months: 90.1191///characteristics_ch1.4: rc_stage: pTa///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 89.88210291///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 10///characteristics_ch1.18: recurrence free survival months (distant and local): 90.1191///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786523/GSM786523.CEL.gz///data_row_count: 54675"
"GSM786524"	"34_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	68	"m"	NA	"n"	NA	"y"	NA	393	"recurrence"	596	"deceased"	"dod"	"former"	60	64.33773142	"2005-05-13"	"title: 34_pT3///geo_accession: GSM786524///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 68.35///characteristics_ch1.3: survival.months: 19.58111///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 64.33773142///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 60///characteristics_ch1.19: recurrence free survival months (distant and local): 12.9117///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786524/GSM786524.CEL.gz///data_row_count: 54675"
"GSM786525"	"35_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	0	NA	NA	69	"f"	NA	"n"	NA	"n"	NA	162	"norecurrence"	162	"deceased"	"doc"	"current"	90	1	"2005-05-13"	"title: 35_pT4///geo_accession: GSM786525///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 68.72///characteristics_ch1.3: survival.months: 5.322382///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 1///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 90///characteristics_ch1.18: recurrence free survival months (distant and local): 5.322382///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786525/GSM786525.CEL.gz///data_row_count: 54675"
"GSM786526"	"36_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	0	NA	NA	84	"m"	NA	"n"	NA	"n"	NA	103	"norecurrence"	103	"living"	"ned"	"former"	40	38.24540238	"2005-05-13"	"title: 36_pT3///geo_accession: GSM786526///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 84.48///characteristics_ch1.3: survival.months: 3.383984///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 38.24540238///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 40///characteristics_ch1.18: recurrence free survival months (distant and local): 3.383984///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786526/GSM786526.CEL.gz///data_row_count: 54675"
"GSM786527"	"37_pTa"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	0	NA	NA	0	0	NA	NA	75	"f"	NA	"n"	NA	"n"	NA	2775	"norecurrence"	2775	"deceased"	"doc"	"current"	60	76.02888814	"2005-05-13"	"title: 37_pTa///geo_accession: GSM786527///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 75.32///characteristics_ch1.3: survival.months: 91.17043///characteristics_ch1.4: rc_stage: pTa///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 76.02888814///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 60///characteristics_ch1.18: recurrence free survival months (distant and local): 91.17043///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786527/GSM786527.CEL.gz///data_row_count: 54675"
"GSM786528"	"38_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	0	NA	NA	91	"f"	NA	"n"	NA	"n"	NA	86	"norecurrence"	86	"deceased"	"doc"	"former"	50	31.81022665	"2005-05-13"	"title: 38_pT3///geo_accession: GSM786528///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 91.08///characteristics_ch1.3: survival.months: 2.825462///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 31.81022665///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 50///characteristics_ch1.18: recurrence free survival months (distant and local): 2.825462///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786528/GSM786528.CEL.gz///data_row_count: 54675"
"GSM786529"	"39_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	57	"m"	NA	"n"	NA	"y"	NA	681	"recurrence"	840	"deceased"	"dod"	"never"	NA	22.16502989	"2005-05-12"	"title: 39_pT3///geo_accession: GSM786529///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 57.33///characteristics_ch1.3: survival.months: 27.59754///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 22.16502989///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 22.37372///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786529/GSM786529.CEL.gz///data_row_count: 54675"
"GSM786530"	"40_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	1	NA	NA	77	"f"	NA	"n"	NA	"y"	NA	210	"recurrence"	302	"deceased"	"dod"	"former"	40	46.44766646	"2005-05-13"	"title: 40_pT3///geo_accession: GSM786530///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 77///characteristics_ch1.3: survival.months: 9.921971///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: NX///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 46.44766646///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 40///characteristics_ch1.19: recurrence free survival months (distant and local): 6.899384///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786530/GSM786530.CEL.gz///data_row_count: 54675"
"GSM786531"	"41_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	81	"m"	NA	"n"	NA	"n"	NA	3124	"norecurrence"	3124	"deceased"	"doc"	"former"	60	43.10781602	"2005-05-13"	"title: 41_pT3///geo_accession: GSM786531///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 80.66///characteristics_ch1.3: survival.months: 102.6366///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 43.10781602///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 60///characteristics_ch1.18: recurrence free survival months (distant and local): 102.6366///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786531/GSM786531.CEL.gz///data_row_count: 54675"
"GSM786532"	"42_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	75	"f"	NA	"n"	NA	"y"	NA	47	"recurrence"	101	"deceased"	"dod"	"former"	58	23.81320156	"2005-05-13"	"title: 42_pT3///geo_accession: GSM786532///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 74.92///characteristics_ch1.3: survival.months: 3.318275///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 23.81320156///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 58///characteristics_ch1.19: recurrence free survival months (distant and local): 1.544148///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786532/GSM786532.CEL.gz///data_row_count: 54675"
"GSM786533"	"43_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	75	"m"	NA	"n"	NA	"y"	NA	206	"recurrence"	3352	"deceased"	"dod"	"former"	30	59.59072639	"2005-05-12"	"title: 43_pT3///geo_accession: GSM786533///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 75.2///characteristics_ch1.3: survival.months: 110.1273///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 59.59072639///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 30///characteristics_ch1.19: recurrence free survival months (distant and local): 6.767967///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786533/GSM786533.CEL.gz///data_row_count: 54675"
"GSM786534"	"44_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	NA	0	NA	NA	88	"m"	NA	"n"	NA	"n"	NA	3220	"norecurrence"	3220	"living"	"ned"	"never"	NA	69.0645029	"2005-05-12"	"title: 44_pT1///geo_accession: GSM786534///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 88.5///characteristics_ch1.3: survival.months: 105.7906///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 69.0645029///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 105.7906///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786534/GSM786534.CEL.gz///data_row_count: 54675"
"GSM786535"	"45_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	0	NA	NA	70	"m"	NA	"n"	NA	"n"	NA	170	"norecurrence"	170	"deceased"	"doc"	"former"	40	20.65263972	"2005-05-13"	"title: 45_pT3///geo_accession: GSM786535///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 69.75///characteristics_ch1.3: survival.months: 5.585216///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 20.65263972///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 40///characteristics_ch1.18: recurrence free survival months (distant and local): 5.585216///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786535/GSM786535.CEL.gz///data_row_count: 54675"
"GSM786536"	"46_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	NA	1	NA	NA	89	"m"	NA	"n"	NA	"n"	NA	184	"recurrence"	233	"deceased"	"dod"	"former"	10	15.38748125	"2005-05-13"	"title: 46_pT4///geo_accession: GSM786536///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 89.46///characteristics_ch1.3: survival.months: 7.655031///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 15.38748125///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 10///characteristics_ch1.18: recurrence free survival months (distant and local): 6.045175///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786536/GSM786536.CEL.gz///data_row_count: 54675"
"GSM786537"	"47_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	1	NA	NA	53	"f"	NA	"n"	NA	"n"	NA	496	"recurrence"	518	"deceased"	"dod"	"former"	NA	82.51542593	"2005-05-12"	"title: 47_pT2///geo_accession: GSM786537///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 53///characteristics_ch1.3: survival.months: 17.01848///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 82.51542593///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: unk///characteristics_ch1.18: recurrence free survival months (distant and local): 16.29569///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786537/GSM786537.CEL.gz///data_row_count: 54675"
"GSM786538"	"48_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	80	"m"	NA	"n"	NA	"n"	NA	1960	"norecurrence"	1960	"deceased"	"doc"	"never"	NA	68.97142268	"2005-05-12"	"title: 48_pT2///geo_accession: GSM786538///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 80.4///characteristics_ch1.3: survival.months: 64.39425///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 68.97142268///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 64.39425///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 2///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786538/GSM786538.CEL.gz///data_row_count: 54675"
"GSM786539"	"49_pTa"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	0	NA	NA	0	0	NA	NA	66	"f"	NA	"n"	NA	"n"	NA	3676	"norecurrence"	3676	"living"	"ned"	"current"	25	54.14254844	"2005-05-03"	"title: 49_pTa///geo_accession: GSM786539///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 66.03///characteristics_ch1.3: survival.months: 120.7721///characteristics_ch1.4: rc_stage: pTa///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 54.14254844///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 25///characteristics_ch1.18: recurrence free survival months (distant and local): 120.7721///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786539/GSM786539.CEL.gz///data_row_count: 54675"
"GSM786540"	"50_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	0	NA	NA	56	"m"	NA	"n"	NA	"y"	NA	1360	"norecurrence"	1360	"living"	"ned"	"current"	30	12.38708981	"2005-05-12"	"title: 50_pT4///geo_accession: GSM786540///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 55.56///characteristics_ch1.3: survival.months: 44.68172///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 12.38708981///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 30///characteristics_ch1.19: recurrence free survival months (distant and local): 44.68172///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786540/GSM786540.CEL.gz///data_row_count: 54675"
"GSM786541"	"51_pTa"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	0	NA	NA	0	0	NA	NA	78	"m"	NA	"n"	NA	"n"	NA	2790	"norecurrence"	2790	"deceased"	"doc"	"former"	10	82.52366144	"2005-05-12"	"title: 51_pTa///geo_accession: GSM786541///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 78.05///characteristics_ch1.3: survival.months: 91.66324///characteristics_ch1.4: rc_stage: pTa///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 82.52366144///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 10///characteristics_ch1.18: recurrence free survival months (distant and local): 91.66324///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786541/GSM786541.CEL.gz///data_row_count: 54675"
"GSM786542"	"52_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	1	NA	NA	69	"f"	NA	"n"	NA	"y"	NA	119	"recurrence"	135	"deceased"	"dod"	"never"	NA	6.797760997	"2005-05-13"	"title: 52_pT4///geo_accession: GSM786542///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 68.7///characteristics_ch1.3: survival.months: 4.435318///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 6.797760997///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 3.909651///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786542/GSM786542.CEL.gz///data_row_count: 54675"
"GSM786543"	"53_pT3"	NA	"tumor"	"rc"	"squamous"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	61	"m"	NA	"n"	NA	"n"	NA	2418	"norecurrence"	2418	"deceased"	"doc"	"never"	NA	68.60720905	"2005-05-12"	"title: 53_pT3///geo_accession: GSM786543///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 61.14///characteristics_ch1.3: survival.months: 79.44148///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC/Squamous///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 68.60720905///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 79.44148///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 2///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786543/GSM786543.CEL.gz///data_row_count: 54675"
"GSM786544"	"54_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	79	"f"	NA	"n"	NA	"y"	NA	77	"recurrence"	416	"deceased"	"dod"	"former"	5	20.63742433	"2005-05-12"	"title: 54_pT3///geo_accession: GSM786544///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 79.39///characteristics_ch1.3: survival.months: 13.66735///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 20.63742433///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 5///characteristics_ch1.19: recurrence free survival months (distant and local): 2.529774///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786544/GSM786544.CEL.gz///data_row_count: 54675"
"GSM786545"	"55_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	0	NA	NA	84	"f"	NA	"n"	NA	"n"	NA	1987	"norecurrence"	1987	"deceased"	"doc"	"former"	50	4.814475736	"2005-05-13"	"title: 55_pT3///geo_accession: GSM786545///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 84.11///characteristics_ch1.3: survival.months: 65.28131///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 4.814475736///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 50///characteristics_ch1.18: recurrence free survival months (distant and local): 65.28131///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786545/GSM786545.CEL.gz///data_row_count: 54675"
"GSM786546"	"56_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	NA	0	NA	NA	84	"m"	NA	"n"	NA	"n"	NA	24	"recurrence"	24	"deceased"	"dod"	"former"	30	23.17374223	"2005-05-13"	"title: 56_pT4///geo_accession: GSM786546///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 83.63///characteristics_ch1.3: survival.months: 0.788501///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 23.17374223///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 0.788501///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786546/GSM786546.CEL.gz///data_row_count: 54675"
"GSM786547"	"57_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	72	"m"	NA	"n"	NA	"y"	NA	42	"recurrence"	410	"deceased"	"dod"	"former"	40	22.55107049	"2005-05-12"	"title: 57_pT3///geo_accession: GSM786547///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 71.91///characteristics_ch1.3: survival.months: 13.47023///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 22.55107049///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 40///characteristics_ch1.19: recurrence free survival months (distant and local): 1.379877///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786547/GSM786547.CEL.gz///data_row_count: 54675"
"GSM786548"	"58_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	75	"m"	NA	"n"	NA	"n"	NA	3329	"norecurrence"	3329	"deceased"	"doc"	"former"	100	76.89741603	"2005-05-13"	"title: 58_pT2///geo_accession: GSM786548///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 74.68///characteristics_ch1.3: survival.months: 109.3717///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 76.89741603///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 100///characteristics_ch1.18: recurrence free survival months (distant and local): 109.3717///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786548/GSM786548.CEL.gz///data_row_count: 54675"
"GSM786549"	"59_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	60	"m"	NA	"n"	NA	"y"	NA	467	"recurrence"	3392	"living"	"ned"	"never"	NA	67.28948158	"2005-05-13"	"title: 59_pT3///geo_accession: GSM786549///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 60.47///characteristics_ch1.3: survival.months: 111.4415///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 67.28948158///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 15.34292///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786549/GSM786549.CEL.gz///data_row_count: 54675"
"GSM786550"	"60_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	81	"m"	NA	"n"	NA	"n"	NA	274	"recurrence"	299	"deceased"	"dod"	"former"	60	57.4680497	"2005-08-03"	"title: 60_pT3///geo_accession: GSM786550///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 81.49///characteristics_ch1.3: survival.months: 9.823409///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 57.4680497///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 60///characteristics_ch1.18: recurrence free survival months (distant and local): 9.002053///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: NA///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786550/GSM786550.CEL.gz///data_row_count: 54675"
"GSM786551"	"61_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	67	"f"	NA	"n"	NA	"y"	NA	3122	"norecurrence"	3122	"living"	"ned"	"never"	NA	66.05294322	"2005-05-13"	"title: 61_pT3///geo_accession: GSM786551///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 67.33///characteristics_ch1.3: survival.months: 102.5708///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 66.05294322///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 102.5708///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786551/GSM786551.CEL.gz///data_row_count: 54675"
"GSM786552"	"62_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	84	"m"	NA	"n"	NA	"n"	NA	237	"norecurrence"	237	"deceased"	"doc"	"former"	40	46.60077495	"2005-05-12"	"title: 62_pT3///geo_accession: GSM786552///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 84.02///characteristics_ch1.3: survival.months: 7.786448///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 46.60077495///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 40///characteristics_ch1.18: recurrence free survival months (distant and local): 7.786448///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786552/GSM786552.CEL.gz///data_row_count: 54675"
"GSM786553"	"63_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	0	NA	NA	69	"m"	NA	"n"	NA	"y"	NA	3101	"norecurrence"	3101	"living"	"ned"	"former"	55	1	"2005-05-12"	"title: 63_pT4///geo_accession: GSM786553///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 69.17///characteristics_ch1.3: survival.months: 101.8809///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 1///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 55///characteristics_ch1.19: recurrence free survival months (distant and local): 101.8809///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786553/GSM786553.CEL.gz///data_row_count: 54675"
"GSM786554"	"64_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	73	"m"	NA	"n"	NA	"n"	NA	993	"norecurrence"	993	"deceased"	"doc"	"current"	120	14.52217463	"2005-05-13"	"title: 64_pT3///geo_accession: GSM786554///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 72.87///characteristics_ch1.3: survival.months: 32.62423///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 14.52217463///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 120///characteristics_ch1.18: recurrence free survival months (distant and local): 32.62423///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786554/GSM786554.CEL.gz///data_row_count: 54675"
"GSM786555"	"65_pT1"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	1	NA	NA	0	0	NA	NA	62	"m"	NA	"n"	NA	"n"	NA	105	"norecurrence"	105	"deceased"	"doc"	"former"	30	90.70677037	"2005-05-03"	"title: 65_pT1///geo_accession: GSM786555///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 62.44///characteristics_ch1.3: survival.months: 3.449692///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 90.70677037///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 3.449692///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786555/GSM786555.CEL.gz///data_row_count: 54675"
"GSM786556"	"66_pTa"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	0	NA	NA	0	0	NA	NA	57	"m"	NA	"n"	NA	"n"	NA	2424	"norecurrence"	2424	"living"	"ned"	"former"	NA	92.15448049	"2005-05-13"	"title: 66_pTa///geo_accession: GSM786556///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 57.37///characteristics_ch1.3: survival.months: 79.6386///characteristics_ch1.4: rc_stage: pTa///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 92.15448049///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: unk///characteristics_ch1.18: recurrence free survival months (distant and local): 79.6386///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786556/GSM786556.CEL.gz///data_row_count: 54675"
"GSM786557"	"67_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	82	"m"	NA	"n"	NA	"n"	NA	3161	"norecurrence"	3161	"deceased"	"doc"	"current"	25	10.62897531	"2005-05-03"	"title: 67_pT3///geo_accession: GSM786557///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 81.5///characteristics_ch1.3: survival.months: 103.8522///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 10.62897531///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 25///characteristics_ch1.18: recurrence free survival months (distant and local): 103.8522///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786557/GSM786557.CEL.gz///data_row_count: 54675"
"GSM786558"	"68_pT1"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	1	NA	NA	NA	0	NA	NA	73	"f"	NA	"n"	NA	"n"	NA	3074	"norecurrence"	3074	"living"	"ned"	"former"	15	54.02532403	"2005-05-12"	"title: 68_pT1///geo_accession: GSM786558///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 72.61///characteristics_ch1.3: survival.months: 100.9938///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: NX///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 54.02532403///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 15///characteristics_ch1.18: recurrence free survival months (distant and local): 100.9938///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786558/GSM786558.CEL.gz///data_row_count: 54675"
"GSM786559"	"69_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	0	0	NA	NA	85	"f"	NA	"n"	NA	"n"	NA	2784	"norecurrence"	2784	"living"	"ned"	"former"	5	79.17928416	"2005-05-12"	"title: 69_pT1///geo_accession: GSM786559///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 85.09///characteristics_ch1.3: survival.months: 91.46612///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 79.17928416///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 5///characteristics_ch1.18: recurrence free survival months (distant and local): 91.46612///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786559/GSM786559.CEL.gz///data_row_count: 54675"
"GSM786560"	"70_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	74	"m"	NA	"n"	NA	"y"	NA	2988	"norecurrence"	2988	"living"	"ned"	"former"	20	62.55822553	"2005-05-03"	"title: 70_pT3///geo_accession: GSM786560///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 74.09///characteristics_ch1.3: survival.months: 98.16838///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 62.55822553///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 20///characteristics_ch1.19: recurrence free survival months (distant and local): 98.16838///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786560/GSM786560.CEL.gz///data_row_count: 54675"
"GSM786561"	"71_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	0	0	NA	NA	79	"m"	NA	"n"	NA	"n"	NA	459	"norecurrence"	459	"deceased"	"doc"	"former"	30	27.19682582	"2005-05-03"	"title: 71_pT4///geo_accession: GSM786561///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 78.82///characteristics_ch1.3: survival.months: 15.08008///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: high///characteristics_ch1.8: nomogram score: 27.19682582///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 15.08008///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786561/GSM786561.CEL.gz///data_row_count: 54675"
"GSM786562"	"72_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	67	"m"	NA	"n"	NA	"n"	NA	202	"norecurrence"	202	"deceased"	"doc"	"former"	10	39.56057988	"2006-04-12"	"title: 72_pT2///geo_accession: GSM786562///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 67.15///characteristics_ch1.3: survival.months: 6.63655///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 39.56057988///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 10///characteristics_ch1.18: recurrence free survival months (distant and local): 6.63655///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786562/GSM786562.CEL.gz///data_row_count: 54675"
"GSM786563"	"73_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	75	"m"	NA	"n"	NA	"y"	NA	204	"recurrence"	387	"deceased"	"dod"	"never"	NA	60.56478669	"2005-05-03"	"title: 73_pT3///geo_accession: GSM786563///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 74.75///characteristics_ch1.3: survival.months: 12.71458///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 60.56478669///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 6.702259///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786563/GSM786563.CEL.gz///data_row_count: 54675"
"GSM786564"	"74_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	66	"m"	NA	"n"	NA	"n"	NA	2047	"norecurrence"	2047	"deceased"	"doc"	"former"	40	17.62653309	"2006-04-12"	"title: 74_pT3///geo_accession: GSM786564///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 66.19///characteristics_ch1.3: survival.months: 67.25257///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 17.62653309///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 40///characteristics_ch1.18: recurrence free survival months (distant and local): 67.25257///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786564/GSM786564.CEL.gz///data_row_count: 54675"
"GSM786565"	"75_pT1"	NA	"tumor"	"rc"	"tcc"	"low"	"superficial"	1	NA	NA	0	0	NA	NA	58	"m"	NA	"n"	NA	"n"	NA	1305	"norecurrence"	1305	"living"	"ned"	"current"	30	67.08968299	"2006-04-12"	"title: 75_pT1///geo_accession: GSM786565///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 57.72///characteristics_ch1.3: survival.months: 42.87474///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: Low///characteristics_ch1.8: nomogram score: 67.08968299///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 42.87474///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786565/GSM786565.CEL.gz///data_row_count: 54675"
"GSM786566"	"76_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	NA	0	NA	NA	79	"m"	NA	"n"	NA	"n"	NA	1581	"norecurrence"	1581	"deceased"	"doc"	"former"	80	61.38268162	"2006-04-13"	"title: 76_pT2///geo_accession: GSM786566///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 78.51///characteristics_ch1.3: survival.months: 51.94251///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 61.38268162///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: DOC///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 80///characteristics_ch1.18: recurrence free survival months (distant and local): 51.94251///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786566/GSM786566.CEL.gz///data_row_count: 54675"
"GSM786567"	"77_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	1	NA	NA	62	"m"	NA	"n"	NA	"y"	NA	148	"recurrence"	457	"deceased"	"dod"	"never"	NA	42.10907773	"2005-05-03"	"title: 77_pT2///geo_accession: GSM786567///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 61.87///characteristics_ch1.3: survival.months: 15.01437///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 42.10907773///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: no///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 4.862423///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786567/GSM786567.CEL.gz///data_row_count: 54675"
"GSM786568"	"78_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	0	NA	NA	70	"m"	NA	"n"	NA	"n"	NA	2579	"norecurrence"	2579	"living"	"ned"	"current"	30	21.11155867	"2005-05-03"	"title: 78_pT3///geo_accession: GSM786568///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 69.63///characteristics_ch1.3: survival.months: 84.73101///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 21.11155867///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Current///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 84.73101///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786568/GSM786568.CEL.gz///data_row_count: 54675"
"GSM786569"	"79_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	0	NA	NA	73	"f"	NA	"n"	NA	"y"	NA	2574	"norecurrence"	2574	"living"	"ned"	"current"	80	10.61219835	"2005-05-03"	"title: 79_pT3///geo_accession: GSM786569///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 72.75///characteristics_ch1.3: survival.months: 84.56674///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 10.61219835///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 80///characteristics_ch1.19: recurrence free survival months (distant and local): 84.56674///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786569/GSM786569.CEL.gz///data_row_count: 54675"
"GSM786570"	"80_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	NA	1	NA	NA	80	"m"	NA	"n"	NA	"n"	NA	495	"recurrence"	536	"deceased"	"dod"	"former"	90	38.72907066	"2005-05-03"	"title: 80_pT3///geo_accession: GSM786570///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 80.46///characteristics_ch1.3: survival.months: 17.60986///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 38.72907066///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 90///characteristics_ch1.18: recurrence free survival months (distant and local): 16.26283///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786570/GSM786570.CEL.gz///data_row_count: 54675"
"GSM786571"	"81_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	0	NA	NA	42	"f"	NA	"n"	NA	"y"	NA	2616	"norecurrence"	2616	"living"	"ned"	"current"	30	71.59866128	"2005-05-03"	"title: 81_pT3///geo_accession: GSM786571///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 41.73///characteristics_ch1.3: survival.months: 85.94661///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 71.59866128///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 30///characteristics_ch1.19: recurrence free survival months (distant and local): 85.94661///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786571/GSM786571.CEL.gz///data_row_count: 54675"
"GSM786572"	"82_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	0	0	NA	NA	75	"m"	NA	"n"	NA	"n"	NA	2712	"norecurrence"	2712	"living"	"ned"	"former"	55	81.6631288	"2006-04-13"	"title: 82_pT1///geo_accession: GSM786572///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 74.82///characteristics_ch1.3: survival.months: 89.10062///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 81.6631288///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 55///characteristics_ch1.18: recurrence free survival months (distant and local): 89.10062///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786572/GSM786572.CEL.gz///data_row_count: 54675"
"GSM786573"	"83_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	58	"m"	NA	"n"	NA	"n"	NA	2469	"norecurrence"	2469	"living"	"ned"	"former"	60	43.42879365	"2005-05-13"	"title: 83_pT2///geo_accession: GSM786573///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: Ta///characteristics_ch1.2: age at rc: 58.21///characteristics_ch1.3: survival.months: 81.11704///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 43.42879365///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 60///characteristics_ch1.18: recurrence free survival months (distant and local): 81.11704///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786573/GSM786573.CEL.gz///data_row_count: 54675"
"GSM786574"	"84_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	51	"m"	NA	"n"	NA	"n"	NA	1300	"norecurrence"	1300	"living"	"ned"	"never"	NA	82.3851487	"2006-04-13"	"title: 84_pT2///geo_accession: GSM786574///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 51.33///characteristics_ch1.3: survival.months: 42.71047///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 82.3851487///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 42.71047///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786574/GSM786574.CEL.gz///data_row_count: 54675"
"GSM786575"	"85_pT4"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	4	NA	NA	1	0	NA	NA	51	"m"	NA	"n"	NA	"y"	NA	1023	"norecurrence"	1023	"living"	"ned"	"former"	40	11.91711954	"2006-04-13"	"title: 85_pT4///geo_accession: GSM786575///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 50.67///characteristics_ch1.3: survival.months: 33.60986///characteristics_ch1.4: rc_stage: pT4///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 11.91711954///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 40///characteristics_ch1.19: recurrence free survival months (distant and local): 33.60986///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: 2///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786575/GSM786575.CEL.gz///data_row_count: 54675"
"GSM786576"	"86_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	48	"m"	NA	"y"	NA	"y"	NA	193	"recurrence"	355	"deceased"	"dod"	"current"	80	61.61975413	"2006-04-13"	"title: 86_pT3///geo_accession: GSM786576///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 47.85///characteristics_ch1.3: survival.months: 11.66324///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 61.61975413///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: Yes///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 80///characteristics_ch1.19: recurrence free survival months (distant and local): 6.340862///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786576/GSM786576.CEL.gz///data_row_count: 54675"
"GSM786577"	"87_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	0	1	NA	NA	68	"f"	NA	"n"	NA	"y"	NA	351	"recurrence"	1000	"deceased"	"dod"	"never"	NA	65.92170237	"2006-04-13"	"title: 87_pT3///geo_accession: GSM786577///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T3///characteristics_ch1.2: age at rc: 68.14///characteristics_ch1.3: survival.months: 32.85421///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 65.92170237///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Never///characteristics_ch1.18: recurrence free survival months (distant and local): 11.53183///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786577/GSM786577.CEL.gz///data_row_count: 54675"
"GSM786578"	"88_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	83	"m"	NA	"n"	NA	"y"	NA	103	"recurrence"	360	"deceased"	"dod"	"current"	40	9.757349648	"2006-04-13"	"title: 88_pT3///geo_accession: GSM786578///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T1///characteristics_ch1.2: age at rc: 82.72///characteristics_ch1.3: survival.months: 11.82752///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 9.757349648///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 1///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: salvage///characteristics_ch1.17: smoking: Current///characteristics_ch1.18: smokingpack-years: 40///characteristics_ch1.19: recurrence free survival months (distant and local): 3.383984///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786578/GSM786578.CEL.gz///data_row_count: 54675"
"GSM786579"	"89_pT1"	NA	"tumor"	"rc"	"tcc"	"high"	"superficial"	1	NA	NA	1	1	NA	NA	69	"m"	NA	"n"	NA	"y"	NA	1560	"recurrence"	1568	"deceased"	"dod"	"former"	10	55.49867656	"2006-04-13"	"title: 89_pT1///geo_accession: GSM786579///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 69.1///characteristics_ch1.3: survival.months: 51.5154///characteristics_ch1.4: rc_stage: pT1///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 55.49867656///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 10///characteristics_ch1.19: recurrence free survival months (distant and local): 51.25257///characteristics_ch1.20: recurrence/dod: Yes///characteristics_ch1.21: cluster: 1///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786579/GSM786579.CEL.gz///data_row_count: 54675"
"GSM786580"	"90_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	1	0	NA	NA	74	"m"	NA	"n"	NA	"y"	NA	1407	"norecurrence"	1407	"living"	"ned"	"former"	60	3.652001993	"2006-04-13"	"title: 90_pT2///geo_accession: GSM786580///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 73.75///characteristics_ch1.3: survival.months: 46.22587///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 3.652001993///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: Yes///characteristics_ch1.16: postchemo type: adjuvant///characteristics_ch1.17: smoking: Former///characteristics_ch1.18: smokingpack-years: 60///characteristics_ch1.19: recurrence free survival months (distant and local): 46.22587///characteristics_ch1.20: recurrence/dod: No///characteristics_ch1.21: cluster: NA///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786580/GSM786580.CEL.gz///data_row_count: 54675"
"GSM786581"	"91_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	0	0	NA	NA	67	"f"	NA	"y"	NA	"n"	NA	2187	"norecurrence"	2187	"living"	"ned"	"never"	NA	78.0425585	"2006-04-13"	"title: 91_pT2///geo_accession: GSM786581///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: female///characteristics_ch1.1: preopclinstage: T4///characteristics_ch1.2: age at rc: 67.38///characteristics_ch1.3: survival.months: 71.85216///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Negative///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 78.0425585///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: Yes///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Never///characteristics_ch1.17: recurrence free survival months (distant and local): 71.85216///characteristics_ch1.18: recurrence/dod: No///characteristics_ch1.19: cluster: 1///characteristics_ch1.20: ///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786581/GSM786581.CEL.gz///data_row_count: 54675"
"GSM786582"	"92_pT3"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	3	NA	NA	1	1	NA	NA	65	"m"	NA	"n"	NA	"n"	NA	74	"recurrence"	174	"deceased"	"dod"	"former"	75	25.7632407	"2006-04-13"	"title: 92_pT3///geo_accession: GSM786582///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 64.83///characteristics_ch1.3: survival.months: 5.716632///characteristics_ch1.4: rc_stage: pT3///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Positive///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 25.7632407///characteristics_ch1.9: distant mets: 1///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 0///characteristics_ch1.12: metastasis: 1///characteristics_ch1.13: last known status: DOD///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 75///characteristics_ch1.18: recurrence free survival months (distant and local): 2.431211///characteristics_ch1.19: recurrence/dod: Yes///characteristics_ch1.20: cluster: 2///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786582/GSM786582.CEL.gz///data_row_count: 54675"
"GSM786583"	"93_pT2"	NA	"tumor"	"rc"	"tcc"	"high"	"invasive"	2	NA	NA	NA	0	NA	NA	78	"m"	NA	"n"	NA	"n"	NA	1965	"norecurrence"	1965	"living"	"ned"	"former"	30	64.19728557	"2005-05-13"	"title: 93_pT2///geo_accession: GSM786583///status: Public on Jan 23 2012///submission_date: Aug 26 2011///last_update_date: Apr 30 2012///type: RNA///channel_count: 1///source_name_ch1: Bladder Cancer///organism_ch1: Homo sapiens///characteristics_ch1: gender: male///characteristics_ch1.1: preopclinstage: T2///characteristics_ch1.2: age at rc: 78.3///characteristics_ch1.3: survival.months: 64.55852///characteristics_ch1.4: rc_stage: pT2///characteristics_ch1.5: rc_histology: TCC///characteristics_ch1.6: plnd result: Nx///characteristics_ch1.7: rc grade: High///characteristics_ch1.8: nomogram score: 64.19728557///characteristics_ch1.9: distant mets: 0///characteristics_ch1.10: local recurrence: 0///characteristics_ch1.11: urothelial recurrence: 1///characteristics_ch1.12: metastasis: 0///characteristics_ch1.13: last known status: NED///characteristics_ch1.14: prerc_chemo: No///characteristics_ch1.15: post rc_chemo: No///characteristics_ch1.16: smoking: Former///characteristics_ch1.17: smokingpack-years: 30///characteristics_ch1.18: recurrence free survival months (distant and local): 64.55852///characteristics_ch1.19: recurrence/dod: No///characteristics_ch1.20: cluster: 1///characteristics_ch1.21: ///treatment_protocol_ch1: Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.///molecule_ch1: total RNA///extract_protocol_ch1: RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols///label_ch1: biotin///label_protocol_ch1: Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).///taxid_ch1: 9606///hyb_protocol: Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays///scan_protocol: Standard Affymetrix protocol.///data_processing: Expression estimates were obtained with GCRMA from Bioconductor with default parameters.///platform_id: GPL570///contact_name: Markus,,Riester///contact_email: markus@jimmy.harvard.edu///contact_laboratory: Michor///contact_department:  Biostatistics & Computational Biology///contact_institute: Dana-Farber Cancer Institute///contact_address: 3 Blackfan Circle///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2115///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM786nnn/GSM786583/GSM786583.CEL.gz///data_row_count: 54675"
